Sign in or create an account to add this stock to your watchlist.
About Tiziana Life Sciences (LON:TILS)
Tiziana Life Sciences plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences plc is a subsidiary of Planwise Group Limited.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:TILS
CUSIPN/A
Phone+44-20-74952379
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-457.77%
Return on Assets-208.53%
Miscellaneous
EmployeesN/A
Outstanding Shares123,830,000
Tiziana Life Sciences (LON:TILS) Frequently Asked Questions
What is Tiziana Life Sciences' stock symbol?
Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."
How were Tiziana Life Sciences' earnings last quarter?
Tiziana Life Sciences (LON:TILS) released its quarterly earnings data on Friday, September, 29th. The biotechnology company reported ($4.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.00) by $2.10. View Tiziana Life Sciences' Earnings History.
What price target have analysts set for TILS?
1 analysts have issued twelve-month price targets for Tiziana Life Sciences' shares. Their forecasts range from GBX 400 to GBX 400. On average, they anticipate Tiziana Life Sciences' stock price to reach GBX 400 in the next year. View Analyst Ratings for Tiziana Life Sciences.
Who are some of Tiziana Life Sciences' key competitors?
Some companies that are related to Tiziana Life Sciences include Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix BioTherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Gr (MVF), Horizon Discovery (HZD), IMV (IMV), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF) and Arix Bioscience (ARIX).
Who are Tiziana Life Sciences' key executives?
Tiziana Life Sciences' management team includes the folowing people:
- Mr. Gabriele Marco Antonio Cerrone, Founder & Exec. Chairman (Age 46)
- Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 60)
- Dr. Philip Boyd BSC, Ph.D., ACMA, Consultant
- Dr. Andrea Brancale Ph.D., Scientific Founder
- Mr. Richard Clarkson Ph.D., Scientific Founder
Has Tiziana Life Sciences been receiving favorable news coverage?
Media stories about TILS stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tiziana Life Sciences earned a media sentiment score of 0.03 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 48.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Tiziana Life Sciences?
Shares of TILS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Tiziana Life Sciences' stock price today?
One share of TILS stock can currently be purchased for approximately GBX 80.25.
How big of a company is Tiziana Life Sciences?
Tiziana Life Sciences has a market capitalization of £122.09 million.
How can I contact Tiziana Life Sciences?
Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.
MarketBeat Community Rating for Tiziana Life Sciences (TILS)
MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences and other stocks. Vote "Outperform" if you believe TILS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TILS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tiziana Life Sciences (LON:TILS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Tiziana Life Sciences in the last 12 months. Their average twelve-month price target is GBX 400The high price target for TILS is GBX 400 and the low price target for TILS is GBX 400. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 400 | GBX 400 | GBX 400 | GBX 0.20 |
Tiziana Life Sciences (LON:TILS) Consensus Price Target History
Tiziana Life Sciences (LON:TILS) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 12/19/2017 | Beaufort Securities | Reiterated Rating | Speculative Buy | GBX 400 |  |
(Data available from 5/22/2016 forward)
Tiziana Life Sciences (LON:TILS) Earnings History and Estimates Chart
Tiziana Life Sciences (LON TILS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/29/2017 | S1 2017 | GBX (2) | GBX (4.10) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Tiziana Life Sciences (LON:TILS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Tiziana Life Sciences (LON TILS) Insider Trading and Institutional Ownership History
Tiziana Life Sciences (LON TILS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Tiziana Life Sciences (LON TILS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Who Are The Largest Shareholders In Tiziana Life Sciences PLC (LON:TILS)?
finance.yahoo.com - May 17 at 3:38 PM |
 | Tiziana Life Sciences (TILS) Stock Rating Reaffirmed by Beaufort Securities
www.americanbankingnews.com - April 15 at 9:47 AM |
| Tiziana Life Sciences PLC (LON:TILS): What Does It Mean For Your Portfolio?
finance.yahoo.com - April 12 at 3:33 PM |
| Tiziana Life Sciences (TILS) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - April 8 at 3:42 PM |
 | Tiziana Life Sciences Raises GBP600,000 Through Share Placing (ALLISS)
www.morningstar.co.uk - March 6 at 3:45 PM |
| Tiziana Life Sciences Raises GBP100,000 Via Share Placing (ALLISS)
www.morningstar.co.uk - January 22 at 4:25 PM |
| Tiziana Life Sciences' (TILS) Speculative Buy Rating Reaffirmed at Beaufort Securities
www.americanbankingnews.com - December 24 at 5:02 PM |
| Tiziana Life Sciences Raise GBP200,000 For Clinical Trial Development (ALLISS)
www.morningstar.co.uk - December 15 at 11:26 AM |
| Tiziana Life Sciences Announces Safety of Milciclib in a Phase 2a Trial in Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients
finance.yahoo.com - December 11 at 4:04 PM |
 | Milciclib Phase 2a Trial Update - London South East (blog)
www.lse.co.uk - December 10 at 10:44 AM |
| Tiziana Life Sciences (TILS) Given Speculative Buy Rating at Beaufort Securities
www.americanbankingnews.com - November 28 at 11:26 PM |
| Tiziana Life Sciences Raises GBP275,000 Via Share Issue (ALLISS)
www.morningstar.co.uk - November 28 at 11:10 AM |
| Tiziana Life Sciences Plc (“Tiziana” or the “Company”): Placing to Raise £275,000
finance.yahoo.com - November 27 at 4:01 PM |
| Phase II Clinical Trial Update - London South East (blog)
www.lse.co.uk - November 25 at 5:54 PM |
| Tiziana Life Sciences Raises GBP150,000 Via Share Issue (ALLISS)
www.morningstar.co.uk - November 20 at 11:04 AM |
| How Does Investing In Tiziana Life Sciences PLC (AIM:TILS) Impact Your Portfolio?
finance.yahoo.com - October 3 at 1:35 PM |
| Motif Bio Share Chat
www.lse.co.uk - October 1 at 7:08 PM |
 | 2 small-cap growth stocks that could make you a millionaire
www.fool.co.uk - September 30 at 7:33 PM |
| Tiziana Life Sciences Interim Loss Widens In "Busy" First Half
www.morningstar.co.uk - September 29 at 10:07 AM |
| Tiziana Life Sciences PLC (TILS) Releases Quarterly Earnings Results, Misses Estimates By $2.10 EPS
www.americanbankingnews.com - September 29 at 8:20 AM |
| Tiziana Life Sciences PLC (TILS) Receives Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - September 10 at 12:44 PM |
| A Proprietary Oral Formulation of Foralumab - London South East (registration) (blog)
www.lse.co.uk - September 7 at 9:58 AM |
| Tiziana Life Sciences Develops Oral Formulation Of Foralumab
www.morningstar.co.uk - September 6 at 9:10 AM |
| Beaufort Securities Reaffirms Speculative Buy Rating for Tiziana Life Sciences PLC (TILS)
www.americanbankingnews.com - August 20 at 5:02 PM |
 | Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy ... - Business Wire (press release)
www.businesswire.com - July 30 at 6:43 AM |
| Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
finance.yahoo.com - July 28 at 8:48 AM |
| Tiziana Life Sciences PLC (LON:TILS) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - July 23 at 10:48 AM |
| Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma
finance.yahoo.com - July 20 at 8:35 AM |
| Proposed changes to CLNs and Warrant Terms - London South East (registration) (blog)
www.lse.co.uk - July 14 at 9:13 AM |
| Bcl-3 pre-clinical update and Director's dealing - London South East (registration) (blog)
www.lse.co.uk - June 10 at 3:24 AM |
| Tiziana Life Sciences Stops Funding For Cardiff University Programme (ALLISS)
www.morningstar.co.uk - June 9 at 1:55 AM |
 | Biotech Is Really Interested in 100-Year-Old Italians
www.bloomberg.com - June 2 at 8:26 PM |
| Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with ... - Business Wire (press release)
www.businesswire.com - April 26 at 3:17 PM |
| Warrant Expiry - Reminder - London South East (registration) (blog)
www.lse.co.uk - January 18 at 12:30 AM |
| Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody - Business Wire (press release)
www.businesswire.com - January 4 at 6:44 AM |
 | Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody
uk.finance.yahoo.com - January 3 at 9:18 AM |
| Half Year 2016 Tiziana Life Sciences PLC Earnings Release - Before Market Open
biz.yahoo.com - September 29 at 10:19 AM |
 | Tiziana Life Sciences PLC: Change of Registered Office
www.streetinsider.com - August 18 at 8:01 PM |
 | Tiziana Life Sciences PLC Announces Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of Equity
www.marketwatch.com - June 29 at 10:31 AM |
| Full Year 2015 Tiziana Life Sciences PLC Earnings Release - Time Not Supplied
biz.yahoo.com - June 7 at 7:07 AM |
| Tiziana reveals possible new anti-cancer molecule
uk.finance.yahoo.com - January 8 at 4:25 AM |
Tiziana Life Sciences (LON:TILS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Tiziana Life Sciences (LON TILS) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
